Biotech Values

[vinmantoo]

I don't think Jake realized that what he posted about ABBV was actually bullish for ENTA

dewophile,

I put Jake on ignore so can't comment on what he wrote. :)

Given that ABBV feels it is worth it to put a Covid Protease inhibitor into trials is indeed a bullish sign for ENTA. I will repeat that it certainly means ABBV could be a potential partner for ENTA.

As far as ABBV, I agree with your analysis that ABBV-903 requiring a drug pump inhibitor almost certainly means it will have similar disadvantages as Paxlovid does in the older population & high risk population.